The top US health insurance lobby, America’s Health Insurance Plans, threw its support behind New York Attorney General Eric Schneiderman and his antitrust case against Actavis.
The lawsuit alleges Actavis altered Namenda IL just enough to replace it with its newer formulation, Namenda IR, prior to its patent expiration. A judge ruled in a preliminary injunction in January that Actavis must keep Namenda IL on the market. AHIP submitted an amicus brief in support of the plaintiff at the end of February.
AHIP spokesperson Ben Jenkins stated in a news release at the time: “This case is an example of what happens when drugmakers engage in anticompetitive behavior under the guise of innovation…forcing a product switch to protect a monopoly punishes consumers in the worst possible way by delaying the entry of more affordable prescription drugs into the market.”
Full Content: Medical Marketing & Media
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Redfin Settles $9.2M Commission Inflation Lawsuits
May 7, 2024 by
CPI
DOJ Supports Colorado’s Efforts to Block Kroger-Albertsons Merger
May 7, 2024 by
CPI
Japan Considers Regulation of AI Developers
May 7, 2024 by
CPI
European Commission Extends Decision Deadline for Ita-Lufthansa Merger
May 7, 2024 by
CPI
UK, US and Australia Sanction Senior Leader of LockBit Cybercrime Gang
May 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI